You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics to acquire CMAB Biopharma Group expresspharma
March 19, 2021
WuXi Biologics announced it has entered into a purchase agreement with CBC Group (CBC), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90 per cent interest of CMAB ...
WuXi Biologics to Acquire Manufacturing Facilities from Pfizer China contractpharma
March 18, 2021
WuXi Biologics has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
BioVaxys, Wuxi Biologics Enter Bioproduction Agreement contractpharma
March 16, 2021
BioVaxys Technology, a provider of haptenized protein vaccines for antiviral and cancer applications, has entered into a major bioproduction agreement with WuXi Biologics, a global contract development and manufacturing organization (CDMO) and ...
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage prnasia
February 01, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
Arcus Biosciences and WuXi Biologics expand deal for antibodies development pharmaceutical-technology
December 11, 2020
Biopharmaceutical company Arcus Biosciences has expanded its existing strategic relationship with Chinese company WuXi Biologics to discover anti-CD39 antibodies using the latter’s proprietary technology.
Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact contractpharma
December 07, 2020
Tubulis, WuXi STA and WuXi Biologics have announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies.
AC Immune and WuXi Biologics Expand Strategic Partnership contractpharma
November 11, 2020
Plan to accelerate AC Immune’s TDP-43 antibody into clinical development.
AB2 Bio and WuXi Biologics Enter Collaboration contractpharma
October 30, 2020
Set-up and accelerate commercial-scale manufacturing of Tadekinig alfa.
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa PharmaSources.com
October 30, 2020
WuXi Biologics and AB2 Bio Ltd., announced that they have entered into a collaboration to set-up and accelerate commercial-scale manufacturing of Tadekinig alfa.
Antengene, WuXi Biologics Ink Innovative Oncology R&D Alliance contractpharma
October 14, 2020
Partner for the development and production of novel drugs, and to jointly promote R&D of innovative oncology therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page